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Abstract 
Background: To investigate the effect of perfluorochemical preparations in enhancing radiotherapy, perfluocarbon 
nanoparticles were by encapsulating perfluorohexane into liposome [lip(PFH)].
Methods: After intravenous injection, lip(PFH) could accumulate in the tumor site over time, with a prominent 
accumulation in tumor 24 h post injection. X-ray was delivered to the tumor site 24 h after the injection of lip(PFH) 
under room air. The experimental mice were randomized into four groups: control (saline), lip(PFH) (lip(PFH) only), 
X-ray (X-ray only), and lip(PFH) + X-ray (lip(PFH) with X-ray radiation). Tumor volume and histology were monitored to 
assess treatment efficacy.
Results: Tumor growth was significantly reduced in mice received lip(PFH) and X-ray compared with X-ray only. The 
histological data also revealed more destruction of tumor tissue in lip(PFH) + X-ray group compared with X-ray only. 
In addition, lip(PFH) did not show any significant tissue damage to major organs or induce significant liver/kidney 
dysfunction.
Conclusions: Lip(PFH) could accumulate in the tumor site and enhance radiotherapy without additional oxygen 
supply.
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Background
Radiotherapy is one of the most frequently used anti-can-
cer therapies. Radiotherapy applies high-energy ionizing 
radiation to destruct tumor cells by producing a free radi-
cal on the DNA to induce DNA damage. Usually, this free 
radical enters into a competition for oxidation or reduc-
tion. Oxidation primarily induced by oxygen could fix 
the damage while reduction primarily induced by—SH-
containing compounds could restore the DNA damage 
[1]. Therefore, the presence of oxygen is crucial for the 
efficacy of radiotherapy. However, hypoxia has been 
well identified in most animal tumor models, as well as 
human tumors, leading to radioresistance in most solid 
tumors [1–3]. It also has been demonstrated that the 
radioresistance of solid tumors is positively correlated 
with oxygen levels in tumor reflected by partial pressure 
of oxygen [4], as well as by the expression of endogenous 
markers of hypoxia, such as hypoxia-inducible factor 1α 
(HIF-1α) [5, 6].
Since the presence of tumor hypoxia is the key mech-
anism involved in radioresistance of solid tumors, sev-
eral strategies have been attempted to sensitize hypoxic 
cells to radiotherapy by supplying oxygen to solid tumor, 
including high oxygen-content gas breathing under 
hyperbaric conditions [2], modified hemoglobin [7, 8], 
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capacity, perfluorocarbons (PFCs) were developed into 
perfluorochemicals emulsions to supply oxygen to 
tumors and thus enhance radiotherapy in preclinical 
studies [9–13]. However, the combination with car-
bogen breathing (95 % O2: 5 % CO2) before and during 
the radiation was indispensable, suggesting very limited 
efficacy of these perfluorochemical emulsions to supply 
oxygen [9, 14]. These perfluorochemicals emulsions were 
intended to increase the oxygen content in circulation 
since they were originally designed as a blood substitute 
[9] or a ultrasound contrast agent [11]. In fact, tumor 
hypoxia is mainly due to the disturbed microcirculation 
and deteriorated diffusion, so that oxygen in circulating 
perfluorocarbons could not enter hypoxic tissue success-
fully [1].
In our previous study, PFC nanoparticles were designed 
to enhance photodynamic therapy (PDT) [15]. Interest-
ingly, improved efficacy of PDT was achieved without 
additional oxygen apply before or during the NIR irradia-
tion. In the present study, PFC nanoparticles were devel-
oped to supply oxygen to the tumor site and therefore 
enhance radiotherapy. Perfluorohexane (PFH) was encap-
sulated into liposome to develop nanoparticles. Radia-
tion was delivered at the time point when lipsome(PFH)
[lip(PFH)] accumulates in the tumor site prominently. 
Compared with the previously reported perfluorochemi-
cal emulsions for sensitization of radiotherapy, the effi-
cacy of lip(PFH) is significantly improved since it delivery 
oxygen directly to the tumor site (Fig. 1). To the best of 
our knowledge, this is the first perfluorochemical prepa-




Lecithin and cholesterol were purchased from Ala-
din Industrial Corporation, and DSPE-PEG2000 was 
obtained from A.V.T. Pharm. Ltd. (Shanghai, China). PFH 
was purchased from Bailingwei Tech Co., Ltd. (Beijing, 
China). IR780 was obtained from Sigma-Aldrich Chemi-
cal Corporation. All animals used in the present study 
were purchased from Medical Center of Yangzhou Uni-
versity (Yangzhou, Jiangsu, China).
Preparation and characterization of lip(PFH)
Lip(PFH) was prepared by ultrasonication according to 
our previously reported study [15]. Briefly, liposome col-
loidal suspensions were prepared by dissolving 3.79  mg 
DSPE-PEG2000 (4.28  mg cholesterol and 24.65  mg 
lecithin in dichloromethane. The organic solvent was 
removed through rotary evaporation to form a thin 
lipids film on the glass vial. Thereafter, the lipid film was 
hydrated with 1.4 ml pure water by ultrasonication (XO-
650D, China) for 10  min in ice bath. After that, 0.6  ml 
PFH were gradually appended under ultrasonication at 
325 w/min for 3  min in ice bath to form 2  ml lip(PFH) 
(30 v/v % PFH). For in vivo tracking, IR780, a near infra-
red (NIR) dye, was added in dichloromethane to form 
lip(PFH + IR780) [15].
The morphology of lip(PFH) was characterized by 
transmission electron microscopy (TEM, H-7650, 
Hitachi, Japan). Particle size distribution of liposomes 
was detected by Nanoparticle Size Analyzer (ZEN3600, 
Malvern). B ultrasound was used to further confirm that 
PFH was encapsulated into liposome.
Animals and tumor model
All experiments were approved by the Institutional Review 
Board of Nanjing University. Male Balb/c mice (~25  g) 
were used to establish allograft tumor model according 
to protocols described before [16]. Briefly, 1 × 107 CT26 
cells (mice colon cancer cells) in 0.2 ml PBS were subcu-
taneously injected into right flank of mice. Fourteen days 
later, the tumor was isolated and cut into small blocks 
(~1 mm3). One tumor block was implanted into the right 
flank of each healthy mouse to establish tumor model. 
When the size of tumor was around 80  mm3, the tumor 
bearing mice were used for each experiment.
Tumor accumulation and imaging
To investigate the distribution of lip(PFH) in tumor bear-
ing Balb/c mice, B ultrasound was used to detect the 
signal of PFH in vivo. Lip(PFH) (1.5 v/v %, 8 ml/kg) was 
intravenously injected into tumor bearing mice. The B 




































Fig. 1 Schematic of the nano-oxygen-carrier for the enhanced 
radiotherapy
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To further confirm the accumulation of lip(PFH) in 
tumor site, IR780, a NIR dye, was loaded into lip(PFH) 
[lip(PFH  +  IR780)] for in  vivo tracking. IVIS Lumina 
imaging system (Xenogen Co., USA, excitation/emission, 
745 nm/ICG) was used to detect the NIR fluorescent sig-
nal in vivo. Lip(PFH +  IR780) (1.5 v/v % PFH, 8 ml/kg) 
was intravenously injected into tumor bearing balb/c 
mice via tail vein. The whole body optical imaging was 
taken 24 h after intravenous injection. Exposure time was 
set to 1 s. Anesthetic animals were placed on an animal 
plate and heated to 37  °C. Images were analyzed using 
IVIS Living Imaging Software. To further confirm the 
distribution of lip(PFH + IR780), three mice were sacri-
ficed 24  h post injection and different organs including 
heart, liver, spleen, lung, kidney, and tumor were isolated 
for NIR fluorescent signal detection.
Radiation therapy
The tumor bearing mice were randomly assigned to 
receive saline (8 ml/kg) (saline + X-ray) or lip(PFH) (1.5 
v/v PFH %, 8 ml/kg) (lip(PFH) + X-ray) 24 h before radi-
otherapy. For radiation delivery, mice were anesthetized 
using 2 % pentobarbital sodium, and received local radi-
ation to the tumors at a dose rate of 1.25 Gy/min using 
6 MV X-rays by linear accelerator (Clinac 600C, Var-
ian Medical System, Palo Alto, CA, USA) under room 
air. Additional two groups of mice received intravenous 
injection of saline (saline) or lip(PFH) [lip(PFH)] without 
X-ray radiation.
Tumor growth time (TGT) assay
After the treatment, the tumor size of each mouse was 
recorded every day using calipers. Tumor volume (V) 
was calculated as V  =  d2*D/2 where D and d are the 
longest and shortest diameter of the tumor respectively. 
Tumor response to the treatment was evaluated by cal-
culating TGT, defined as the time required for the initial 
tumor volume to grow tenfold after treatment [9]. Tumor 
growth delay (TGD) time was calculated by the follow-
ing formula: TGD of each tumor = TGT (treated) of each 
tumor-average TGT of control group.
Histological analysis
Twenty-four hours after treatment, three mice in each 
group were sacrificed and tumors were harvested, fixed 
in 10 % formalin, processed routinely into paraffin, sec-
tioned (5  μm) for histological analysis. Tissue sections 
were stained with hematoxylin and eosin (H&E) using a 
commercial available kit (Jiancheng Biotechnology, Nan-
jing, China) according to the protocol provided by the 
manufacturer.
Quantitative determination of apoptosis in tumor sec-
tions was assessed by a terminal transferase-mediated 
dUTP nick-end labeling (TUNEL) assay using an In Situ 
Cell Death Detection Kit (Roche, Basel, Switzerland). 
After dewaxing and rehydration, the tissue sections were 
permeabilized with 0.1 % Triton X-100 for 10 min. Incu-
bation with label solution was used to detect the apop-
totic cells according to the instructions. Apoptotic score 
was achieved by counting the number of positive nuclei 
in 10 random fields.
Toxicity of lip(PFH) to CT26 cells and healthy mice
The toxicity of lip(PFH) was investigated using CT26 
cells. Cell-viability was determined by cell-counting 
kit-8 (CCK-8) assay (Jiancheng Biotechnology, Nanjing, 
China). Briefly, CT26 cells were plated in 96-well flat-
bottomed plates with a concentration of 4000 cells per 
well and allowed to grow overnight prior to incubation 
with lip(PFH) with different concentrations from 1.25 
v/v PFH % to 5 % v/v PFH %. 24 h later, culture medium 
containing lip(PFH) was changed with fresh RPMI-1640 
medium and CCK-8 was added to each well for an addi-
tional 2 h. The cell viability was determined by measur-
ing the absorption at 450 nm using a microplate reader 
(Safire, TECAN, USA).
The toxicity of lip(PFH) to healthy male mice was con-
ducted by injecting lip(PFH) (1.5 v/v PFH  %, 8  ml/kg) 
via tail vein. Mice injected with saline were set as con-
trol. Two weeks after injection, major organs from each 
mouse were harvested, fixed in 10 % formalin, processed 
routinely into paraffin, sectioned, stained with hematox-
ylin and eosin (H&E) and examined by a digital micro-
scope. Examined tissues include heart, liver, spleen, lung 
and kidney. In addition, blood serum was collected for 
biochemistry assay of liver and renal function using com-
mercially available kits.
Statistical analysis
Data were analyzed using Prism 4 (GraphPad Software, 
San Diego, CA, USA) and expressed as mean ± standard 
deviation. Multiple groups were compared using multi-
variate analysis of variance or one-way ANOVA followed 
by the Tukey–Kramer test for post hoc comparisons. Stu-
dent t test was used to compare the difference between 
two groups. Statistical significance was set at P < 0.05.
Results
Preparation and characterization of lip(PFH)
PFH was encapsulated into liposome to form lip(PFH) 
with a core of PFH and a shell of lipid (Fig.  2a). TEM 
showed that these oxygen-carriers were spherical vesi-
cles (Fig. 2b) with an average diameter of 100 nm. From 
the results of dynamic light scattering (DLS), the size of 
lip(PFH) was 106.1 nm with low variation (Fig. 2c), which 
was consistent with that measured by TEM. As shown 
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in Fig.  2d, enhanced contrast signal was observed in 
lip(PFH) by using B ultrasound, further confirming that 
PFH was encapsulated into liposome.
Accumulation of lip(PFH) in tumor site
Since lip(PFH) could be detected by B ultrasound, the 
accumulation of lip(PFH) in tumor site was confirmed by 
B ultrasound. As shown in Fig. 3a, the ultrasound imag-
ing showed that lip(PFH) tended to accumulate in the 
tumor over time, with prominent accumulation in tumor 
24 h post injection.
Lip(PFH  +  IR780) was prepared to further confirm 
the accumulation of PFH in the tumor site. As shown 
in Fig.  3b, the accumulation of lip(PFH  +  IR780) in 
tumor site was detected 24  h post injection, which was 
consistent with the results obtained from B ultrasound. 
To further confirm the accumulation of lip(PFH + IR780) 
in tumor, fluorescence in tumor and main organs (Fig. 3c, 
d) was detected 24 h after injection of lip(PFH + IR780). 
The results revealed that the tumors had stronger NIR 
fluorescence signal, confirming the accumulation of 
lip(PFH) in tumor.
The effect of lip(PFH) on sensitizing tumor to radiotherapy
TGT and TGD were used to evaluate the tumor response 
to the treatment. According to the results from mul-
tivariate analysis of variance, the TGT was affected by 
X-ray (P < 0.01), Lip(PFH) (P < 0.01),and X-ray*Lip(PFH) 
(P  <  0.05) significantly. Furthermore,compared with 
that in mice treated with saline or lip(PFH) only, TGT 
c









Fig. 2 Characterization of the nano-oxygen-carrier. a Schematic of the nano-oxygen-carrier. b TEM image of the nano-oxygen carrier. c Size distri-
bution of the nano-oxygen-carrier. d Ultrasound images of the nano-oxygen carrier and other groups tested in 5 ml plastic test tubes
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and TGD in mice treated with X-ray was significantly 
increased. In addition, significantly increased TGT, and 
TGD were observed when lip(PFH) was injected 24  h 
before X-ray radiation, suggesting significantly enhanced 
tumor response to X-ray (Fig. 4a, b).
To further investigate the tumor response to the treat-
ment, 3 mice in each group were sacrificed 48  h after 
injection and the tumor from saline + was harvested for 
histological analysis. Compared with the saline +  X-ray 
group, more necrosis was observed in the tumor sec-
tion from lip(PFH) + X-ray group (Fig. 5a). As shown in 
Fig. 5b, c, tumors from mice injected with lip(PFH) 24 h 
before radiation contained a significantly greater number 
of TUNEL-positive apoptotic cells compared with that 
from mice treated with saline and X-ray. This data fur-
ther confirm that administration of lip(PFH) before X-ray 
irradiation enhance tumor response to X-ray.
Toxicity of lip(PFH) to CT26 cells and healthy mice
The potential toxicity of lip(PFH) to CT26 cells was eval-
uated by CCK-8 assay. From the results, no dark toxic-
ity of the micelles was observed in CT26 cells after 24 h 
incubation with lip(PFH) even at the highest concentra-
tion (5 % v/v PFH %) (Fig. 6a).
The potential toxicity of nano-oxygen-carrier was 
conducted by injecting lip(PFH) (1.5 v/v PFH  %, 8  ml/
kg) to healthy Balb/c mice via tail vein. The histological 
data revealed that there was no noticeable tissue damage 
in all the major organs of mice at therapeutic dose (1.5 
v/v PFH  %, 8  ml/kg) in comparison with control group 
(Fig. 6b). The results suggest no obvious toxicity in histo-
logical level of mice is induced by lip(PFH).
The main liver function markers including alanine ami-
notransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), gamma-glutamyl trans-
peptidase (GGT), adenosine deaminase (ADA), total bile 
acid (TBA), total bilirubin (TBIL), albumin/globin ratio 
(A/G), lactate dehydrogenase (LDH) (Fig.  6b) as well as 
kidney function markers including serum urea (UREA), 
serum creatinine (CREA) and uric acid (URIC) (Fig. 6c) 
were all measured. All these results obtained at 2 weeks 
post injection did not show significant difference com-
pared with control group. These results suggested no 
obvious hepatic or kidney disorder of mice induced by 
lip(PFH) (Tables 1, 2).
Discussion
Due to its ability of carrying oxygen, perfluorochemi-
cal emulsions were originally designed as blood substi-
tutes to replace the O2 carrying capacity of the blood to 
provide adequate O2 perfusion, and thus to resuscitate 
patients in hemorrhagic shock after traumatic injuries 
























Fig. 3 Accumulation of the nano-oxygen-carrier in tumor site. a Ultrasound imaging of the nano-oxygen carrier in tumor-bearing mice after intra-
venous injection of lip(PFH). Images were taken at 6–72 h post-injection. Tumors were circled by white dash line. b Near-infrared imaging of IR780 in 
tumor-bearing mice after intravenous injection of lip(IR780 + PFH). Imagines were taken 24 h post-injection. Tumors were circled by blue dash line. 
c Near-infrared imaging of IR780 in the different organs from tumor-bearing mice 24 h post-injection of lip(IR780 + PFH). d Quantitation of near-
infrared signals in the organs from tumor-bearing mice 24 h post-injection of lip(IR780 + PFH). *P < 0.05 compared with tumor
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[17]. Since hypoxia is the key mechanism involved in 
the redioresistance of solid tumors, PFCs were also 
developed for radiosensitization since 1980s.Fluosol-
DA has been shown to be effective in enhancing the 
response of several solid tumors to radiotherapy both in 
preclinical studies [9, 18–22] and some clinical studies 
[17, 23]. Due to the poor stability of Fluosol-DA, sev-
eral other improved perfluorochemical emulsions have 
been developed for radiosensitization [11–13]. Usually, 
PFCs were delivered shortly before radiation (e.g. 1  h) 
and intended to increase the oxygen content in cir-
culation and thus enhance radiotherapy in the most 
reported studies [9, 11, 14, 24, 25]. Despite the effect of 
perfluorochemical emulsions on radiosensitization, the 
efficacy of perfluorochemical emulsions seemed to be 
very limited since oxygen breathing (95 % O2 or 100 % 
O2) before and during the radiotherapy was indispensa-


















































Fig. 4 The effect of the nano-oxygen-carrier in delaying the growth of tumor. a Tumor growth time of CT26 tumor. Growth time of CT26 tumor 
produced by different dosage (0, 5, 7.5, 10 Gy) of X-ray radiation 24 h after administration of saline or lip(PFH). Each column represents mean ± SD 
of 6 mice. *P < 0.05 compared with saline group. b Growth delay time of CT26 tumor. Tumor growth delay of CT26 tumor produced by by different 
dosage (0, 5, 7.5, 10 Gy) of X-ray radiation 24 h after administration of saline or lip(PFH). Each column represents mean ± SD of 6 mice. *P < 0.05 
compared with saline group
Fig. 5 The effect of the nano-oxygen-carrier on the histology of tumor. a H&E staining of the tumor section. Twenty four hours after IV injection of 
saline or lip(PFH), the tumor was irradiated with X-ray (10 Gy). One day after irradiation, tumors were dissected for H&E staining. The white bar indi-
cates 200 μm. b TUNEL staining of the tumor section. Twenty four hours after IV injection of saline or lip(PFH), the tumor was irradiated with X-ray 
(10 Gy). One day after irradiation, tumors were dissected for TUNEL staining. Brown signal indicates apoptotic cells. c Quantitation of apoptotic cells 
in saline and lip(PFH) groups. *P < 0.05 compared with saline group
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were originally designed to replace the O2 carrying 
capacity of the blood to provide adequate O2 perfusion, 
and thus to resuscitate patients in hemorrhagic shock 
after traumatic injuries [17]. Therefore, PFCs were 
delivered shortly before radiation (e.g. 1 h) and intended 
to increase the oxygen content in circulation and thus 
enhance radiotherapy in the most reported studies [9, 
11, 14, 24, 25].
However, the vascular network is pathological in most 
solid tumors [26]. Different from that in normal tissues, 
vascular network in tumor is chaotic, dilated, and tortu-
ous [3, 27]. Due to the accelerated proliferation of cancer 
cells, hypoxic regions arise in tumor tissue distant from 
blood vessels. In addition to these regions of chronic 
hypoxia (also defined as diffusion-limited hypoxia), tem-
porary closure of blood vessels can develop acute hypoxia 
(perfusion-limited hypoxia) [1, 9, 28]. Since the diffusion 
distance of oxygen is typically around 150  μm [2], very 
limited oxygen in circulating PFCs could diffuse to the 
tumor tissue which is distant from the vessels. In addi-
tion, temporary obstruction of tumor vessels occurs, 
resulting failure of delivering oxygen in circulating PFCs 
to tumor tissue. That might be the reason why the effi-
cacy of perfulorochemical emulsions to enhance radio-
therapy in the previous studies was very limited, since the 
oxygen in circulating perfulorochemical emulsions could 
not diffuse to the tumor site successfully.
In our previously published study, improved PDT 
was achieved by delivering both oxygen-carrying PFH 
and photosensitizer to the tumor site [15]. This give us 
inspiration to enhance radiotherapy by delivering oxy-
gen-carrying PFH into the tumor site. Infrared laser was 
delivery 24 h after injection of PFH when the PFH arrived 
prominent accumulation in tumor. This give us inspira-
tion to enhance the efficacy of PFCs for radiotherapy. 
In the present study, PFC nanoparticles were developed 
by encapsulating PFH into liposome to supply oxygen 
directly to the tumor site. X-ray was delivery 24  h after 
lip(PFH) injection, when lip(PFH) arrived the prominent 
accumulation in the tumor site. The results indicated that 
lip(PFH) sensitize the tumor to radiotherapy significantly 
(Fig.  4) even x-ray radiation was delivered without any 
additional oxygen breathing. The difference between the 
saline group and the lip(PFH) group is not that notable 
but significant. It might be due that only once lip(PFH) 
was administrated during the present study. Further 
studies will be conducted to investigate how to enhance 
this radiosensitization effect of lip(PFH).
The accumulation of lip(PFH) in tumor site is essential 
for direct supply of oxygen. Data obtained from in  vivo 
NIR fluorescent imaging and B ultrasound shows great 
accumulation of lip(PFH) in the solid tumor 24  h after 
intravenous injection (Fig. 3), which was consistent with 
the results in our previously reported study [15]. This 
might be mainly due to the nano-size of lip(PFH) which 
was developed to be with an average diameter of 100 nm. 
The size of lip(PFH) is small enough to avoid clearance by 
the reticuloendothelial system (RES) and to permeate into 
tumor tissue through enhanced permeability and reten-
tion (EPR) effect. In addition to the nano-size, the adop-
tion of PEG as a stealth moiety on the surface of lip(PFH) 
could extend the resident time in  vivo [29, 30], further 
contributing to the great tumor accumulation. Some 
other mechanisms such as hypoxic conditions in the 
tumor site recruit lip(PFH) might exit, which need further 
investigations. After accumulating in tumor site, oxygen 
in PFH could be released directly to the tumor site, short-
ening the diffusion distance between oxygen carriers and 
the tumor cells. In addition, x-ray radiation was delivered 
after accumulation of the oxygen carriers in the tumor 
site. Therefore, oxygen in PFH could be released directly 
to the tumor site even the tumor vessels are temporarily 
obstructed before or during the radiotherapy.
Oxygen release in the tumor site is another essen-
tial factor for the enhance radiosensitization. From 
both in  vivo NIR fluorescent imaging and B ultrasound 
data, PFC nanoparticles were observed to be accumu-
lated in tumor site with a prominent accumulation in 
tumor 24  h post injection. Therefore, x-ray radiation 
was delivered 24 h post injection of lip(PFH) in the pre-
sent study. Unlike hemoglobin, where oxygen is bound 
to the molecule to form chelates, oxygen is physically 
dissolved in PFCs without any chemical process [31]. 
Therefore, oxygen solubility expressed as partial pres-
sure (pO2) approaches a linear function in PFCs, unlike 
the saturation level in hemoglobin. In addition, the gas 
molecules situate themselves in the spaces between the 
molecules [31]. The uptake and release of oxygen from 
PFCs are completely reversible, and the rate is twice as 
fast as chelation to hemoglobin. After accumulating in 
the tumor site, the dissolved oxygen could be released 
because of the low pO2 in tumor tissue. Because of its 
high capacity of oxygen, PFH in the tumor site could also 
collect oxygen from the near tissue when the contained 
oxygen was exhausted.
Conclusions
PFC nanoparticles were designed to supply oxygen 
directly to the tumor site for the enhancement of radio-
therapy. Radiation was delivered when the nanoparti-
cles accumulated in tumor site. Improved radiotherapy 
was achieved without additional oxygen breathing, sug-
gesting new perspectives of applying PFC to enhance 
radiotherapy.
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The concentration of PHF
Fig. 6 Toxicity of the nano-oxygen-carrier on healthy mice. a Cell viability of CT26 cells treated by different concentration of lip(PFH). Cell viability 
was indicated by CCK-8. b H&E staining images of major organs including heart, liver, spleen, lung, kidney and skine. Two weeks after IV injection of 
saline or lip(PFH), the mice were sacrificed and the tumors were dissected for H&E staining. The white bar indicates 200 μm
Table 1 Serum level of liver function markers in mice 2w after injection of saline or lip(PFH) (1.5 v/v PFH %, 8 ml/kg)
n = 3
ALT (U/l) AST (U/l) AKP (U/l) GGT (U/l) ADA (U/l) TBA (μmol/l) TBIL (μmol/l) A/G LDH (U/l)
Saline 48.86 ± 3.79 86.16 ± 13.25 176.8 ± 16.32 1.0 ± 0.15 4.2 ± 0.38 0.8 ± 0.07 0.5 ± 0.06 1.22 ± 0.09 361 ± 38.1
Lip(PFH) 49.67 ± 6.89 87.68 ± 6.89 169.6 ± 15.74 1.0 ± 0.09 4.2 ± 0.47 0.8 ± 0.06 0.5 ± 0.08 1.23 ± 0.12 324 ± 46.5
Table 2 Serum level of renal function markers in mice 2w 
after injection of saline or lip(PFH) (1.5 v/v PFH %, 8 ml/kg)
n = 3
UREA (mmol/l) CREA (μmol/l) URIC (μmol/l)
Control 8.86 ± 1.02 4.13 ± 1.02 13.87 ± 1.53
Lip(PFH) 8.12 ± 0.94 3.98 ± 0.89 13.56 ± 1.04
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